Business
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
VIENNA, Va., July 11, 2025--CEL-SCI to sign partnership agreement with leading Saudi Arabian pharma company for Multikine in the treatment of head & neck cancer.
About this update from Cel-sci Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":240,"url":"https://media.zenfs.com/en/business-wire.com/f631072b681d533db8d5e974de9ba09a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/e_MQ2jaJ48IXQ0TEKtFPFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f631072b681d533db8d5e974de9ba09a","width":480,"height":240}},"lazy":false},{"type":"text","content":"Strong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East and North Africa market","length":151,"tagName":"p","attribs":{}},{"type":"text","content":"Patient access and reimbursement/sale in Saudi Arabia within approximately 60 days following filing for Breakthrough Medicine Designation","length":137,"tagName":"p","attribs":{}},{"type":"text","content":"VIENNA, Va., July 11, 2025--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced it has reached an agreement with one of Saudi Arabia’s premier pharmaceutical and healthcare companies for a partnership that spans regulatory and commercial activities for Multikine* (Leukocyte Interleukin, Injection) in the Kingdom of Saudia Arabia. The formal agreement is expected to be signed with the Saudi pharmaceutical partner which will file a Breakthrough Medicine Designation application for Multikine with the Saudi Food and Drug Authority (SFDA) in the coming weeks. According to the SFDA, the response time to a Breakthrough Medicine Designation application is approximately 60 days. Following the granting of the Breakthrough Medicine Designation, Multikine would immediately become available for patient access and reimbursement/sale in Saudi Arabia. Several leading Saudi funds have expressed interest in investing in Multikine, CEL-SCI, and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market.","length":1053,"tagName":"p"},{"type":"text","content":"While CEL-SCI has the option of filing for Breakthrough Medicine Designation directly, the Company made a strategic decision to collaborate with its local partner for the regulatory filing and subsequent commercial distribution in Saudi Arabia. In a prior meeting with the SFDA, the Saudi regulatory agency provided guidance and...